Loading...
Loading...
RANI| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.8M |
| Operating I/L | -11.8M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.4M |
| Pretax | -12.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -6.8M |
Rani Therapeutics Holdings, Inc. is a clinical stage biotherapeutics company specializing in the development of orally administered biologics. The company's flagship product, the RaniPill capsule, aims to replace traditional subcutaneous or IV injections with oral dosing. Their product pipeline includes a range of biologics such as octreotide for neuroendocrine tumors and acromegaly, anti-TNF-alpha antibody for psoriatic arthritis, parathyroid hormone for osteoporosis, human growth hormone for growth hormone deficiency, parathyroid hormone for hypoparathyroidism, and basal insulin for type 2 diabetes.
